|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.612 USD | +2.71% |
|
+2.71% | +8.95% |
| 05-29 | Aptose Biosciences Says Acquisition by Hanmi Delayed Until June | MT |
| 05-29 | Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed | RE |
Company Valuation: Aptose Biosciences Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 389.8 | 121.6 | 53.19 | 20.15 | 13.59 | 3.947 |
| Change | - | -68.8% | -56.27% | -62.12% | -32.53% | -70.97% |
| Enterprise Value (EV) 1 | 268.5 | 43.09 | 7.535 | 11.91 | 18.08 | 30.22 |
| Change | - | -83.95% | -82.51% | 58.06% | 51.81% | 67.16% |
| P/E Ratio | -6.5x | -1.86x | -1.27x | -0.33x | -0.19x | -0.15x |
| PBR | 3.28x | 1.7x | 1.41x | -6.94x | -2.99x | -0.15x |
| PEG | - | -0.21x | 0x | -0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -4.83x | -0.66x | -0.18x | -0.23x | -0.69x | -1.22x |
| EV / EBIT | -4.81x | -0.66x | -0.18x | -0.23x | -0.69x | -1.22x |
| EV / FCF | -20.4x | -1.66x | -0.45x | -0.46x | -0.68x | -2.41x |
| FCF Yield | -4.89% | -60.4% | -220% | -217% | -147% | -41.5% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -303.7 | -330.1 | -204 | -227.4 | -36.38 | -10.41 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -55.62 | -65.3 | -42.48 | -52.27 | -26.22 | -24.7 |
| EBIT 1 | -55.77 | -65.45 | -42.6 | -52.36 | -26.26 | -24.72 |
| Net income 1 | -55.24 | -65.35 | -41.82 | -51.21 | -25.43 | -25.47 |
| Net Debt 1 | -121.3 | -78.55 | -45.66 | -8.237 | 4.487 | 26.28 |
| Reference price 2 | 1,974.181 | 615.177 | 259.343 | 76.100 | 6.776 | 1.546 |
| Nbr of stocks (in thousands) | 197 | 198 | 205 | 265 | 2,006 | 2,552 |
| Announcement Date | 3/23/21 | 3/22/22 | 3/24/23 | 3/26/24 | 3/28/25 | 3/31/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.15x | 12.05x | 24.81x | 0.6% | 1,010B | |
| 25.74x | 5.93x | 16.13x | 2.22% | 580B | |
| 27.88x | 6.79x | 13.86x | 3.01% | 402B | |
| 17.71x | 4.37x | 10.73x | 3.04% | 330B | |
| 21.24x | 5.49x | 13.32x | 2.92% | 281B | |
| 22.78x | 4.74x | 13.47x | 1.85% | 280B | |
| 12.7x | 4.76x | 9.73x | 3.95% | 197B | |
| 23.09x | 6.16x | 10.76x | 2.84% | 192B | |
| -45x | 5.43x | 29.95x | 2.58% | 156B | |
| Average | 15.48x | 6.19x | 15.86x | 2.56% | 380.99B | |
| Weighted average by Cap. | 22.68x | 7.47x | 17.41x | 2.09% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- APS Stock
- APTO.F Stock
- Valuation Aptose Biosciences Inc.
Select your edition
All financial news and data tailored to specific country editions
